Charlotte L Bevan
Overview
Explore the profile of Charlotte L Bevan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
989
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Broomfield J, Kalofonou M, Bevan C, Georgiou P
Biosensors (Basel)
. 2024 Sep;
14(9).
PMID: 39329818
Current diagnostic and prognostic tests for prostate cancer require specialised laboratories and have low specificity for prostate cancer detection. As such, recent advancements in electrochemical devices for point of care...
2.
Kalofonou F, Leach D, Powell S, Waxman J, Fletcher C, Bevan C
Front Oncol
. 2024 Sep;
14:1440612.
PMID: 39267821
In most patients with advanced prostate cancer treated with hormonal therapy, androgen independence eventually emerges, leading to death. Androgen receptor signalling remains an important prostate cancer driver, even in the...
3.
Dart D, Bevan C, Uysal-Onganer P, Jiang W
Sci Rep
. 2024 May;
14(1):11115.
PMID: 38750183
Androgen deprivation therapy (ADT) is the core treatment for advanced prostate cancer (PCa), with a proven survival benefit. ADT lowers circulating testosterone levels throughout the body, but with it comes...
4.
Ogunjinmi O, Abdullahi T, Somji R, Bevan C, Barclay W, Temperton N, et al.
J Med Virol
. 2024 Mar;
96(3):e29540.
PMID: 38529542
The sex disparity in COVID-19 outcomes with males generally faring worse than females has been associated with the androgen-regulated expression of the protease TMPRSS2 and the cell receptor ACE2 in...
5.
Constantin T, Varela-Carver A, Greenland K, Serrano de Almeida G, Olden E, Penfold L, et al.
Br J Cancer
. 2024 Feb;
130(5):892.
PMID: 38355841
No abstract available.
6.
Broomfield J, Kalofonou M, Franklin S, Powell S, Pataillot-Meakin T, Moser N, et al.
IEEE Sens Lett
. 2023 Aug;
7(8):1-4.
PMID: 37529707
Ion-sensitive field-effect transistors (ISFETs) in combination with unmodified complementary metal oxide semiconductors present a point-of-care platform for clinical diagnostics and prognostics. This work illustrates the sensitive and specific detection of...
7.
Leach D, Fernandes R, Bevan C
Endocr Oncol
. 2023 Jul;
2(1):R112-R131.
PMID: 37435460
Androgen signalling, through the transcription factor androgen receptor (AR), is vital to all stages of prostate development and most prostate cancer progression. AR signalling controls differentiation, morphogenesis, and function of...
8.
Constantin T, Varela-Carver A, Greenland K, Serrano de Almeida G, Olden E, Penfold L, et al.
Br J Cancer
. 2023 Apr;
128(12):2326-2337.
PMID: 37076563
Background: Current strategies to inhibit androgen receptor (AR) are circumvented in castration-resistant prostate cancer (CRPC). Cyclin-dependent kinase 7 (CDK7) promotes AR signalling, in addition to established roles in cell cycle...
9.
Penfold L, Woods A, Pollard A, Arizanova J, Pascual-Navarro E, Muckett P, et al.
Cell Rep
. 2023 Apr;
42(4):112396.
PMID: 37061917
Emerging evidence indicates that metabolic dysregulation drives prostate cancer (PCa) progression and metastasis. AMP-activated protein kinase (AMPK) is a master regulator of metabolism, although its role in PCa remains unclear....
10.
Buxton A, Abbasova S, Bevan C, Leach D
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551674
Prostate cancer-associated deaths arise from disease progression and metastasis. Metastasis to the liver is associated with the worst clinical outcomes for prostate cancer patients, and these metastatic tumors can be...